News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Social Media Suggests an MS Dogfight Between Biogen, Inc. and Novartis AG (NVS)



5/24/2013 8:28:41 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Over the past month, surveying the track record for the newly launched Tecfidera multiple sclerosis pill has become a closely watched exercise on Wall Street. Each week, analysts pore over prescription data to gauge the extent to which the drug, which is sold by Biogen Idec, is capturing market share and how many billions of dollars in sales may be generated this year (back story).

Hey, check out all the research scientist jobs. Post your resume today!

Read at PharmaLive


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES